Last reviewed · How we verify

AGN-223575 ophthalmic solution

Allergan · Phase 2 active Small molecule

AGN-223575 ophthalmic solution is a corticosteroid used to treat inflammation in the eye.

AGN-223575 ophthalmic solution is a corticosteroid used to treat inflammation in the eye. Used for Treatment of inflammation in the eye.

At a glance

Generic nameAGN-223575 ophthalmic solution
SponsorAllergan
Drug classCorticosteroid
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 2

Mechanism of action

AGN-223575 ophthalmic solution works by suppressing the immune system's response to inflammation in the eye, thereby reducing swelling and pain. This is achieved through the inhibition of phospholipase A2, a key enzyme involved in the inflammatory process. By reducing inflammation, AGN-223575 ophthalmic solution helps to promote healing and prevent further damage to the eye.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results